Key result
Switching from acenocoumarol to apixaban resolves leukocytoclastic vasculitis in a patient with previous hypersensitivity.
This case highlights leukocytoclastic vasculitis as a rare adverse reaction to coumarin derivatives that was successfully resolved by transitioning to apixaban.
May warrant apixaban trial in coumarin-associated vasculitis; hypothesis-generating case report requiring prospective validation.
Coumarin derivatives, including warfarin and acenocoumarol, are widely used oral anticoagulants that inhibit vitamin K-dependent coagulation factors. They are commonly prescribed for the prophylaxis of thromboembolic disorders. Although effective, these agents are associated with many adverse drug reactions, which include hemorrhagic complications, warfarin-induced skin necrosis, hypersensitivity reactions, and, rarely, leukocytoclastic vasculitis (LCV). LCV is an immune-mediated small-vessel vasculitis characterised by palpable purpura, often triggered by drugs, infections, or autoimmune conditions. Here, we present the case of a 53-year-old female with a history of rheumatic heart disease and mechanical mitral valve replacement who developed LCV after 5 years on acenocoumarol. The reaction persisted despite adjunct therapy and worsened upon switching to warfarin, suggesting possible cross-reactivity between these coumarin derivatives. Ultimately, transitioning to apixaban led to the complete resolution of symptoms. This case underscores the importance of early recognition of drug-induced vasculitis and highlights the need for individualised anticoagulation strategies in patients with hypersensitivity reactions.
No takes yet. Share an insight, caveat, or question.
Mahadevappa et al. (2025) studied this question. Transitioning from acenocoumarol to apixaban resulted in complete resolution of leukocytoclastic vasculitis symptoms in a patient with previous hypersensitivity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: